Mepolizumab 750 mg vs placebo
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 3 [0.22, 40.93]1 study · 18 participantsLow